Provider variability in intensity modulated radiation therapy utilization among Medicare beneficiaries in the United States
Authors:
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Practical Radiation Oncology
- Vol. 8 (5) , e329-e336
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Medicare Physician-Data Release — Context and RationaleNew England Journal of Medicine, 2014
- Public Disclosure of Medicare Payments to Individual Physicians2014
- Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicitiesLung Cancer, 2013
- Predictors of IMRT and Conformal Radiotherapy Use in Head and Neck Squamous Cell Carcinoma: A SEER-Medicare AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Adoption of Intensity-Modulated Radiation Therapy for Breast Cancer in the United StatesJNCI: Journal of the National Cancer Institute, 2011
- Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate CancerJournal of Clinical Oncology, 2011
- Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRTRadiotherapy and Oncology, 2009
- Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studiesThe Lancet Oncology, 2008
- Intensity‐modulated radiation therapy use in the U.S., 2004Cancer, 2005